Histone deacetylase inhibitors in multiple myeloma: Rationale and evidence for their use in combination therapy

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 4, 2013, Pages 370-376

  Kaufman, Jonathan L ^a   Fabre, Claire ^b   Lonial, Sagar ^a   Richardson, Paul G ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Hematologic malignancy; Histone modification; Immunomodulatory agent; Proteasome inhibitor

Indexed keywords

ACY 1215; ALKYLATING AGENT; BELINOSTAT; CARFILZOMIB; DEXAMETHASONE; DOXORUBICIN; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; PANOBINOSTAT; PREDNISONE; PROTEASOME INHIBITOR; ROMIDEPSIN; THALIDOMIDE; TUBACIN; UCL 67022; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ADJUVANT THERAPY; AGGRESOME; ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MOTILITY; CELL SURVIVAL; CYTOTOXICITY; DEACETYLATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LYSOSOME; MULTIPLE MYELOMA; MYELOMA CELL; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FOLDING; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; UBIQUITINATION;

HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; IMMUNOMODULATORY AGENT; PROTEASOME INHIBITOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MULTIPLE MYELOMA;

EID: 84880737018     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.016     Document Type: Review

References (79)

1. S. Jagannath, M.A. Dimopoulos, and S. Lonial Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma Leuk Res 34 2010 1111 1118
2. M.A. Dimopoulos, J.F. San-Miguel, and K.C. Anderson Emerging therapies for the treatment of relapsed or refractory multiple myeloma Eur J Haematol 86 2010 1 15
3. S.V. Rajkumar Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management Am J Hematol 87 2012 78 88
4. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
5. S.K. Kumar, J.H. Lee, and J.J. Lahuerta Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study Leukemia 26 2012 149 157
6. V. Scudla, M. Ordeltova, and J. Bacovsky The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma Haematologica 90 2005 1713 1714 (Pubitemid 41815005)
7. D.P. Steensma, M.A. Gertz, and P.R. Greipp A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death Blood 97 2001 2522 2523 (Pubitemid 32291501)
8. T. Hideshima, N. Nakamura, and D. Chauhan Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma Oncogene 20 2001 5991 6000 (Pubitemid 32955041)
9. L. Stimson, V. Wood, and O. Khan HDAC inhibitor-based therapies and haematological malignancy Ann Oncol 20 2009 1293 1302
10. H. Adams, F.R. Fritzsche, and S. Dirnhofer Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma Expert Opin Ther Targets 14 2010 577 584
11. L. Marquard, L.M. Gjerdrum, and I.J. Christensen Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma Histopathology 53 2008 267 277
12. J.C. Wang, C. Chen, and T. Dumlao Enhanced histone deacetylase enzyme activity in primary myelofibrosis Leuk Lymphoma 49 2008 2321 2327
13. T. Wada, J. Kikuchi, and N. Nishimura Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors J Biol Chem 284 2009 30673 30683
14. P.A. Marks, and W.S. Xu Histone deacetylase inhibitors: potential in cancer therapy J Cell Biochem 107 2009 600 608
15. L. Stimson, and N.B. La Thangue Biomarkers for predicting clinical responses to HDAC inhibitors Cancer Lett 280 2009 177 183
16. C. Choudhary, C. Kumar, and F. Gnad Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 325 2009 834 840
17. T. Robert, F. Vanoli, and I. Chiolo HDACs link the DNA damage response, processing of double-strand breaks and autophagy Nature 471 2011 74 79
18. T.E. Fandy, S. Shankar, and D.D. Ross Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma Neoplasia 7 2005 646 657 (Pubitemid 41099418)
19. N. Mitsiades, C.S. Mitsiades, and P.G. Richardson Molecular sequelae of histone deacetylase inhibition in human malignant B cells Blood 101 2003 4055 4062 (Pubitemid 36857886)
20. R. Niesvizky, S. Ely, and T. Mark Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma Cancer 117 2011 336 342
21. N. Khan, M. Jeffers, and S. Kumar Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem J 409 2008 581 589 (Pubitemid 351184977)
22. A.B. Hanker, K.D. Healy, and J. Nichols Romidepsin inhibits Ras-dependent growth transformation of NIH 3T3 fibroblasts and RIE-1 epithelial cells independently of Ras signaling inhibition J Mol Signal 4 2009 5
23. D. Chauhan, T. Hideshima, and C. Mitsiades Proteasome inhibitor therapy in multiple myeloma Mol Cancer Ther 4 2005 686 692 (Pubitemid 40601851)
24. E.A. Obeng, L.M. Carlson, and D.M. Gutman Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells Blood 107 2006 4907 4916 (Pubitemid 43882644)
25. G. Bianchi, L. Oliva, and P. Cascio The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition Blood 113 2009 3040 3049
26. S. Meister, U. Schubert, and K. Neubert Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition Cancer Res 67 2007 1783 1792 (Pubitemid 46383406)
27. T. Hideshima, P. Richardson, and D. Chauhan The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells Cancer Res 61 2001 3071 3076 (Pubitemid 32691956)
28. F. Parlati, S.J. Lee, and M. Aujay Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome Blood 114 2009 3439 3447
29. NCCN. Clinical Practice Guidelines in Oncology. Multiple myeloma. V1.2012 [Web site]. Available at: www.nccn.org. Accessed: March 27, 2012.
30. ClinicalTrials.gov [Web site]. Phase 3 study comparing carfilzomib, lenalidomide, and dexamethasone (CRd) versus lenalidomide and dexamethasone (Rd) in subjects with relapsed multiple myeloma. Available at: http://www. clinicaltrials.gov/ct2/show/NCT01080391?term=NCT01080391&rank=1. Accessed: March 27, 2012.
31. KYPROLIS™ (carfilzomib) for injection [package insert] 2012 Onyx Pharmaceuticals South San Francisco, CA
32. B. Hoang, A. Benavides, and Y. Shi Effect of autophagy on multiple myeloma cell viability Mol Cancer Ther 8 2009 1974 1984
33. X.Y. Pei, Y. Dai, and S. Grant Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors Clin Cancer Res 10 2004 3839 3852 (Pubitemid 38697620)
34. L. Maharaj, R. Popat, and A. Chahwan The novel HDAC inhibitor UCL67022 is highly potent in multiple myeloma and non-Hodgkin's lymphoma and is enhanced by bortezomib Blood 108 2006 (abstract 2604)
35. C. Mitsiades, P.G. Richardson, and S. Grant Vorinostat in combination with other anti-MM agents Clin Lymphoma Myeloma 9 2009 2 S117
36. C. Boyault, Y. Zhang, and S. Fritah HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates Genes Dev 21 2007 2172 2181 (Pubitemid 47360839)
37. E.L. Davenport, H.E. Moore, and A.S. Dunlop Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells Blood 110 2007 2641 2649 (Pubitemid 47523188)
38. R. Nimmanapalli, L. Fuino, and P. Bali Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells Cancer Res 63 2003 5126 5135 (Pubitemid 37022654)
39. P. Bali, M. Pranpat, and J. Bradner Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 2005 26729 26734 (Pubitemid 41040705)
40. L. Catley, E. Weisberg, and T. Kiziltepe Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 2006 3441 3449
41. T. Hideshima, J.E. Bradner, and J. Wong Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci U S A 102 2005 8567 8572 (Pubitemid 40862776)
42. L. Santo, T. Hideshima, and A.L. Kung Selective inhibition of HDAC6 with a new prototype inhibitor (ACY-1215) overcomes bortezomib resistance in multiple myeloma (MM) Blood 116 2010 (abstract 2997)
43. S.T. Nawrocki, J.S. Carew, and K.H. Maclean Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA Blood 112 2008 2917 2926
44. V.M. Richon, J. Garcia-Vargas, and J.S. Hardwick Development of vorinostat: current applications and future perspectives for cancer therapy Cancer Lett 280 2009 201 210
45. J. Kikuchi, T. Wada, and R. Shimizu Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma Blood 116 2010 406 417
46. C.S. Mitsiades, N.S. Mitsiades, and C.J. McMullan Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci U S A 101 2004 540 545 (Pubitemid 38084672)
47. E.M. Ocio, D. Vilanova, and P. Atadja In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma Haematologica 95 2010 794 803
48. R.A. Campbell, E. Sanchez, and J. Steinberg Vorinostat enhances the antimyeloma effects of melphalan and bortezomib Eur J Haematol 84 2010 201 211
49. E. Sanchez, J. Shen, and J. Steinberg The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo Leuk Res 35 2011 373 379
50. C.K. Lee, S. Wang, and X. Huang HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells Cancer Lett 296 2010 233 240
51. T. Hideshima, P.L. Bergsagel, and W.M. Kuehl Advances in biology of multiple myeloma: clinical applications Blood 104 2004 607 618 (Pubitemid 38970551)
52. P. Richardson, C. Mitsiades, and K. Colson Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma Leuk Lymphoma 49 2008 502 507 (Pubitemid 351298334)
53. S. Schmitt, A.D. Ho, and H. Goldschmidt The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide Onkologie 33 2010 183 186
54. J.L. Wolf, D. Siegel, and J. Matous A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma Blood 112 2008 (abstract 2774)
55. D.S. Siegel, M.A. Dimopoulos, and S.S. Yoon VANTAGE 095: final results from a global, single-arm, phase 2b trial of vorinostat in combination with bortezomib in salvage multiple myeloma patients Haematologica 97 suppl 1 2012 119 (abstract 0294)
56. M.A. Dimopoulos, S. Jagannath, and S.S. Yoon VANTAGE 088: final results from the global phase 3 trial of the multihistone deacetylase inhibitor vorinostat in combination with bortezomib in relapsed/refractory multiple myeloma Haematologica 93 suppl 1 2012 113 (abstract 0281)
57. M. Offidani, F. Cavallo, and C. Polloni Melphalan, thalidomide and prednisone (MPT) combined with oral panobinostat in patients with relapsed/refractory MM: a phase I-II study Blood 116 2010 (abstract 3019)
58. R.L. Schlossman, M. Alsina, and D.M. Weber PANORAMA 2: a phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma Haematologica 96 suppl 2 2011 327 (abstract 0900)
59. J.F. San-Miguel, S. Lonial, and V. Hungria PANORAMA1: a randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma J Clin Oncol 29 15 suppl 2011 (abstract TPS227)
60. S.J. Harrison, H. Quach, and K. Yuen High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial Blood 112 2008 (abstract 3698)
61. S.A. Ruell, M. Prince, and H. Quach Cardiac safety of one versus four hour romidepsin (Istodax®) infusion in the setting of a phase I/II trial of romidepsin, dexamethasone and bortezomib for relapsed or refractory multiple myeloma Blood 116 2010 (abstract 5037)
62. D. Weber, A.Z. Badros, and S. Jagannath Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: early clinical experience Blood 112 2008 871
63. A. Badros, A.M. Burger, and S. Philip Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 2009 5250 5257
64. D.M. Weber, S. Jagannath, and A. Mazumder Phase I trial of oral vorinostat in combination with bortezomib in advanced multiple myeloma Haematologica 93 suppl 1 2008 257 (abstract 0640)
65. D.S. Siegel, L. McBride, and E. Bilotti Vorinostat overcomes lenalidomide-dexamethasone and lenalidomide-bortezomib-dexamethasone resistance in relapsed/refractory multiple myeloma Blood 116 2010 (abstract 3065)
66. A. Mazumder, D.H. Vesole, and S. Jagannath Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice Clin Lymphoma Myeloma Leuk 10 2010 149 151
67. Y. Alsayed, B.P. Nair, and M. Kauffman Carfilzomib (CFZ) in combination with DEX and other agents (Dox, Thal, DDP, vorinostat) for far advanced and refractory multiple myeloma (FARMM) J Clin Oncol 28 2010 e18504
68. J. San Miguel, O. Sezer, and D. Siegel A phase Ib dose-escalation study of oral panobinostat (LBH589) and IV bortezomib in patients with relapsed or relapsed and refractory multiple myeloma Haematologica 95 suppl 2 2010 155 (abstract 0384)
69. S.J. Harrison, H. Quach, and E. Link A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma Blood 118 2011 6274 6283
70. P. Richardson, D. Weber, and C.S. Mitsiades A phase I study of vorinostat, lenalidomide, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: excellent tolerability and promising activity in a heavily pretreated population Blood 116 2010 (abstract 1951)
71. M. Mateos, A. Spencer, and K. Taylor Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM) J Clin Oncol 28 suppl 15 2010 (abstract 8030)
72. J.R. Berenson, O. Yellin, and R.V. Boccia A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM) Blood 114 2009 (abstract 1855)
73. P.M. Voorhees, C. Gasparetto, and K. Osman Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma Blood 116 2010 (abstract 1955)
74. J.S. Kerr, S. Galloway, and A. Lagrutta Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat Int J Toxicol 29 2010 3 19
75. P.N. Munster, E.H. Rubin, and S. Van Belle A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer Clin Cancer Res 15 2009 7077 7084
76. L. Zhang, D. Lebwohl, and E. Masson Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat) J Clin Oncol 26 2008 332 333 discussion 3-4
77. A. Cashen, M. Juckett, and A. Jumonville Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS) Ann Hematol 91 2012 33 38
78. W.M. Stadler, K. Margolin, and S. Ferber A phase II study of depsipeptide in refractory metastatic renal cell cancer Clin Genitourin Cancer 5 2006 57 60
79. P.G. Richardson, C. Mitsiades, and R. Schlossman New drugs for myeloma Oncologist 12 2007 664 689 (Pubitemid 47036203)